Inter-cohort and clinical centers collaboration of subjects co-infected by human immunodeficiency virus and hepatitis C FRESH-PEF3626-en Laure ESTERLE Inter-cohort and clinical centers collaboration of subjects co-infected by human immunodeficiency virus and hepatitis C ANRS C013 HEPAVIH FRESH-PEF3626-en 3626 FRESH-PEF3626 Laure ESTERLE Dominique SALMON Philippe SOGNI AGENCE NATIONALE DE RECHERCHES SUR LE SIDA ET LES HEPATITES VIRALES (ANRS MIE) Epidemiology France Portal (PEF) AGENCE NATIONALE DE RECHERCHES SUR LE SIDA ET LES HEPATITES VIRALES (ANRS MIE) F. HOFFMANN-LA ROCHE AG GLAXOSMITHKLINE (FRANCE) INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) JANSSEN CILAG (JANSSEN - JOHNSON & JOHNSON - JOHNSON & JOHNSON INNOVATIVE MEDICINE) MERCK SANTE null Linda;WITTKOP Dominique;SALMON Philippe;SOGNI Adults disease carriers cured treatment co-infection Clinical immunology Infectious disease medicine HIV disease clinical stage 2 without mention of tuberculosis or malaria Viral hepatitis Behavioral determinants Short term: - Describe patient's characteristics - Analyze factors associated to a treatment of hepatitis C: beginning of the treatment, continuation or stop of the treatment. - Validate the field performance of not-invasive markers of hepatic fibrosis. Mid-term: - Realize an observational study of the evolution of hepatitis during an anti-VHC treatment, in an antiviral situation - Study the clinical and biological tolerance to the different treatments. - Study the impact of the observance of the treatment anti HIV and the life quality of patients. Long term: Study the natural history of chronic hepatitis, in particular at the stage of cirrhosis. - Analyze the factors associated to the evolution to fibrosis, to a decompensated hepatic disease or an hepatocellular carcinoma. - Evaluate the effects of antiretroviral agents on the evolution of not-treated hepatitis - Study the potential interactions between different virus of hepatitis null France Individuals Patients population Male Female Other Young Adult (19 to 24 years) Adult (25 to 44 years) Middle Aged (45 to 64 years) Aged (65 to 79 years) Adults infected by HIV virus carriers of VHC or cured after anti-VHC treatment, or spontaneously healed without anti-VHC treatment or benefiting from an anti-VHC tritherapies. Clinical data Participant-reported health data Biological data Paraclinical data (non-biological) : Imaging --- Data utilization possible for academic teams and for industrials. Temporary access condition : project accepted by the scientific committee Health care consumption and services Quality of life/health perception Other Through organizations (health services or institutions schools businesses etc.) [1000-10000[ individuals Self-administered questionnaire Interview with the participant (including clinical) Observational Study Observational Study Cohort study 1849 in june 2018 Unknown Restricted access Data utilization possible for academic teams and for industrials. Temporary access condition : project accepted by the scientific committee Temporary access condition : project accepted by the scientific committee Access on specific project only